Leerink Partnrs Brokers Lift Earnings Estimates for CureVac

CureVac (NASDAQ:CVAC) – Investment analysts at Leerink Partnrs raised their FY2025 EPS estimates for CureVac in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($0.54) per share for the year, up from their prior estimate of ($0.60). The consensus estimate for CureVac’s current full-year earnings is $0.72 per share.

CureVac Price Performance

Shares of NASDAQ:CVAC opened at $3.96 on Friday. The stock has a market capitalization of $886.56 million, a P/E ratio of 7.20 and a beta of 2.50. The business has a 50-day moving average of $3.31 and a two-hundred day moving average of $3.19. CureVac has a fifty-two week low of $2.21 and a fifty-two week high of $5.28. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19.

Institutional Investors Weigh In On CureVac

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. bought a new position in shares of CureVac in the second quarter valued at approximately $8,237,000. Barclays PLC acquired a new position in CureVac in the 3rd quarter valued at $67,000. Public Employees Retirement System of Ohio bought a new position in CureVac in the 3rd quarter worth $91,000. Jane Street Group LLC raised its holdings in CureVac by 239.0% in the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock worth $235,000 after acquiring an additional 55,867 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in CureVac by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock worth $127,000 after acquiring an additional 16,792 shares during the last quarter. 17.26% of the stock is currently owned by institutional investors and hedge funds.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.